
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Neurosci., 31 July 2023
Sec. Translational Neuroscience
Volume 17 - 2023 | https://doi.org/10.3389/fnins.2023.1237920
This article is a correction to:
Phase I trial outcome of amnion cell therapy in patients with ischemic stroke (I-ACT)
A corrigendum on
Phase I trial outcome of amnion cell therapy in patients with ischemic stroke (I-ACT)
by Phan, T. G., Lim, R., Krause, M., Chan, S. T., McDonald, H., Gan, P.-Y., Zhang, S. R., Barreto Arce, L. J., Vuong, J., Thirugnanachandran, T., Clissold, B., Ly, J., Singhal, S., Hervet, M. V., Kim, H. A., Drummond, G. R., Wallace, E. M., Ma, H., and Sobey, C. G. (2023). Front. Neurosci. 17:1153231. doi: 10.3389/fnins.2023.1153231
In the published article, there was an error in the author list, and author “Mirja Krause” was erroneously excluded. The corrected author list and author contributions section are appears below.
“Thanh G. Phan1, 2*, Rebecca Lim3, 4, Mirja Krause3, 4, Siow T. Chan3, 4, Hannah McDonald3, 4, Poh-Yi Gan5, 6, Shenpeng R. Zhang7, Liz J. Barreto Arce7, Jason Vuong1, 2, Tharani Thirugnanachandran1, 2, Benjamin Clissold1, 2, John Ly1, 2, Shaloo Singhal1, 2, Marie Veronic Hervet1, 2, Hyun Ah Kim7, Grant R. Drummond7, Euan M. Wallace4, 8, Henry Ma1, 2 and Christopher G. Sobey7*”
TP, HMa, RL, EW, and CS designed the trial protocol and were major contributors in the writing of the manuscript. JV performed image analysis. TT, BC, JL, and SS recruited patients and performed clinical assessments. RL, MK, SC, and HMc prepared cells for administration to patients. MH administered cell infusions and collected the patient data. P-YG, SZ, LB, and HK performed the analyses of blood samples for inflammatory markers. CS and GD analyzed the data. All authors contributed to the article and approved the submitted version.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: stem cell, clinical trial, ischemic stroke, phase I, allogeneic
Citation: Phan TG, Lim R, Krause M, Chan ST, McDonald H, Gan P-Y, Zhang SR, Barreto Arce LJ, Vuong J, Thirugnanachandran T, Clissold B, Ly J, Singhal S, Hervet MV, Kim HA, Drummond GR, Wallace EM, Ma H and Sobey CG (2023) Corrigendum: Phase I trial outcome of amnion cell therapy in patients with ischemic stroke (I-ACT). Front. Neurosci. 17:1237920. doi: 10.3389/fnins.2023.1237920
Received: 10 June 2023; Accepted: 21 July 2023;
Published: 31 July 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Phan, Lim, Krause, Chan, McDonald, Gan, Zhang, Barreto Arce, Vuong, Thirugnanachandran, Clissold, Ly, Singhal, Hervet, Kim, Drummond, Wallace, Ma and Sobey. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Thanh G. Phan, dGhhbmgucGhhbkBtb25hc2guZWR1; Christopher G. Sobey, Yy5zb2JleUBsYXRyb2JlLmVkdS5hdQ==
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.